• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受抗CD20治疗的患者的双相性COVID-19临床病程:病例系列及文献综述

A Biphasic COVID-19 Clinical Course in Anti-CD20 Treated Patients: Case Series and Review of the Literature.

作者信息

Bigman-Peer Noa, Peer Eyal, Pertzov Barak, Kramer Mordechai, Segal Gad, Eliakim-Raz Noa

机构信息

Department of Internal Medicine E, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.

Oncology Institute, Sheba Medical Center, Ramat Gan, Israel.

出版信息

Eur J Case Rep Intern Med. 2022 Aug 31;9(8):003502. doi: 10.12890/2022_003502. eCollection 2022.

DOI:10.12890/2022_003502
PMID:36093299
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9451519/
Abstract

UNLABELLED

We describe four cases of COVID-19 infection during the Omicron wave, in patients treated with anti-CD20 monoclonal antibodies. All cases follow a similar biphasic clinical course consisting of respiratory deterioration, which occurred a few weeks after convalescence from initial mild to asymptomatic infection. Possible explanations are discussed.

LEARNING POINTS

Four cases of COVID-19 infection in anti-CD20 treated patients are described.These cases display a unique biphasic course that was previously undescribed: respiratory deterioration weeks after convalescence.Awareness of such a course and rapid utilisation of bronchoalveolar lavage will lead to quicker diagnosis and more timely, appropriate treatment.

摘要

未标注

我们描述了在奥密克戎毒株流行期间,接受抗CD20单克隆抗体治疗的患者中4例新冠病毒感染病例。所有病例均呈现相似的双相临床病程,包括呼吸功能恶化,这发生在从最初的轻度至无症状感染康复数周后。文中讨论了可能的原因。

学习要点

描述了4例接受抗CD20治疗的患者感染新冠病毒的病例。这些病例呈现出一种此前未被描述过的独特双相病程:康复数周后出现呼吸功能恶化。认识到这种病程并迅速进行支气管肺泡灌洗将有助于更快诊断并更及时、恰当地进行治疗。

相似文献

1
A Biphasic COVID-19 Clinical Course in Anti-CD20 Treated Patients: Case Series and Review of the Literature.接受抗CD20治疗的患者的双相性COVID-19临床病程:病例系列及文献综述
Eur J Case Rep Intern Med. 2022 Aug 31;9(8):003502. doi: 10.12890/2022_003502. eCollection 2022.
2
Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies.病例报告:在利妥昔单抗诱导的血清病和抗利妥昔单抗抗体合并难治性免疫性血小板减少症的患者中,使用奥滨尤妥珠单抗作为替代单克隆抗 CD20 抗体。
Front Immunol. 2022 Apr 19;13:863177. doi: 10.3389/fimmu.2022.863177. eCollection 2022.
3
Incidence, Clinical Presentation, Relapses and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Patients Treated With Anti-CD20 Monoclonal Antibodies.抗 CD20 单克隆抗体治疗患者严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染的发生率、临床表现、复发和结局。
Clin Infect Dis. 2022 May 30;74(10):1786-1794. doi: 10.1093/cid/ciab700.
4
COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.7 例接受抗 CD20 治疗的多发性硬化症患者合并 COVID-19。
Mult Scler Relat Disord. 2020 Sep;44:102306. doi: 10.1016/j.msard.2020.102306. Epub 2020 Jun 15.
5
Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with Zr in Human Lymphoma Xenografts.评估 Zr 标记的新一代抗 CD20 抗体在人淋巴瘤异种移植模型中的疗效。
J Nucl Med. 2018 Aug;59(8):1219-1224. doi: 10.2967/jnumed.117.203299. Epub 2018 Jan 18.
6
Obinutuzumab in hematologic malignancies: lessons learned to date.奥滨尤妥珠单抗在血液恶性肿瘤中的应用:迄今为止的经验教训。
Cancer Treat Rev. 2015 Nov;41(9):784-92. doi: 10.1016/j.ctrv.2015.07.003. Epub 2015 Jul 14.
7
Obinutuzumab in follicular lymphoma.奥妥珠单抗治疗滤泡性淋巴瘤。
Drugs Today (Barc). 2016 Dec;52(12):643-651. doi: 10.1358/dot.2016.52.12.2550578.
8
Obinutuzumab for B-cell malignancies.奥滨尤妥珠单抗用于治疗B细胞恶性肿瘤。
Expert Opin Biol Ther. 2014 Aug;14(8):1197-205. doi: 10.1517/14712598.2014.922535. Epub 2014 May 23.
9
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.利妥昔单抗:用于非霍奇金淋巴瘤和慢性淋巴细胞白血病的综述
Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.
10
Late onset neutropenia after rituximab and obinutuzumab treatment - characteristics of a class-effect toxicity.利妥昔单抗和奥妥珠单抗治疗后迟发性中性粒细胞减少症——一种类效应毒性的特征
Leuk Lymphoma. 2021 Dec;62(12):2921-2927. doi: 10.1080/10428194.2021.1948037. Epub 2021 Jul 21.

引用本文的文献

1
COVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?慢性淋巴细胞白血病患者中的新冠病毒肺炎:我们了解到了什么?
Acta Haematol. 2024;147(1):60-72. doi: 10.1159/000534540. Epub 2023 Oct 11.
2
Prolonged SARS-CoV-2 Infection and Organizing Pneumonia in a Patient with Follicular Lymphoma, Treated with Obinutuzumab-Challenging Recognition and Treatment.滤泡性淋巴瘤患者在接受奥滨尤妥珠单抗治疗后出现持续性 SARS-CoV-2 感染和机化性肺炎:具有挑战性的识别和治疗。
Viruses. 2023 Mar 7;15(3):693. doi: 10.3390/v15030693.

本文引用的文献

1
Progression of COVID-19 in a Patient on Anti-CD20 Antibody Treatment: Case Report and Literature Review.1例接受抗CD20抗体治疗的COVID-19患者的病情进展:病例报告与文献综述
Case Rep Infect Dis. 2022 Feb 25;2022:8712424. doi: 10.1155/2022/8712424. eCollection 2022.
2
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.接受利妥昔单抗治疗的炎症性风湿和肌肉骨骼疾病患者的COVID-19结局:一项队列研究。
Lancet Rheumatol. 2021 Jun;3(6):e419-e426. doi: 10.1016/S2665-9913(21)00059-X. Epub 2021 Mar 25.
3
Adaptive immunity to SARS-CoV-2 and COVID-19.对 SARS-CoV-2 和 COVID-19 的适应性免疫。
Cell. 2021 Feb 18;184(4):861-880. doi: 10.1016/j.cell.2021.01.007. Epub 2021 Jan 12.
4
Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab.利妥昔单抗治疗后B细胞耗竭患者的新冠病毒病呈现长程、复发性及非典型症状病程
Semin Arthritis Rheum. 2020 Oct;50(5):1087-1088. doi: 10.1016/j.semarthrit.2020.06.013. Epub 2020 Jun 30.
5
Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain.多发性硬化症及相关疾病中的抗CD20与COVID-19:来自西班牙马德里的60例患者病例系列
Mult Scler Relat Disord. 2020 Jul;42:102185. doi: 10.1016/j.msard.2020.102185. Epub 2020 May 7.